GlassScriptPhysician profile
John T Dedousis
NPI 1164515706
$13,880.25
in general payments reported to CMS, 2019-2025
51 companies · $1,851 in 2025
The $1,851 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,617 · 2020: $1,600 · 2021: $2,998 · 2022: $1,880 · 2023: $2,226 · 2024: $1,708 · 2025: $1,851.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,768 · Education: $16.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,768.30 |
| Education | $16.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,587.20 | 2021-2025 | Vraylar, Qulipta, Linzess |
| Biohaven Pharmaceuticals, INC. | $1,319.27 | 2021 | |
| Novo Nordisk INC | $1,223.30 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $1,076.92 | 2019-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $1,037.25 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $1,000.35 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $666.46 | 2019-2025 | Farxiga |
| Pfizer INC. | $563.75 | 2019-2025 | |
| Allergan, INC. | $522.78 | 2019-2020 | |
| Medtronic, INC. | $499.13 | 2022-2025 | Minimed 780g, Minimed 770g, Inpen Smart Insulin Delivery System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $415.14 | 2019-2025 | Jardiance, Stiolto Respimat |
| Corcept Therapeutics | $298.51 | 2025 | Korlym |
| Amarin Pharma, INC. | $236.43 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $212.33 | 2021-2025 | |
| Mylan Specialty L.P. | $207.88 | 2019-2024 | Yupelri |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Dedousis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.